Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study

Table 6 AUC-ROC, continuous net reclassification improvement index and integrated discrimination improvement index when each biomarker was added to the clinical model ^a

	Severe AKI			In-hospital mortality
	AUC-ROC	Continuous NRI	IDI	AUC-ROC	Continuous NRI	IDI
Clinical model	0.87 (0.76 to 0.94)			0.72 (0.57 to 0.83)
+ NGAL	0.89 (0.77 to 0.95)	25 (−19 to 69)	0.03 (−0.00 to 0.07)	0.72 (0.58 to 0.83)	24 (−31 to 79)	0.00 (−0.01 to 0.01)
+ IL-6	0.88 (0.76 to 0.94)	−8 (−51 to 35)	0.00 (−0.00 to 0.01)	0.72 (0.58 to 0.83)	10 (−44 to 64)	0.01 (−0.02 to 0.04)
+ EPO	0.88 (0.75 to 0.94)	34 (−10 to 78)	0.01 (−0.01 to 0.03)	0.72 (0.57 to 0.83)	−13 (−68 to 42)	0.00 (−0.00 to 0.01)
+ TIMP-2	0.89 (0.76 to 0.95)	41 (1 to 82)^b	0.04 (0.00 to 0.08)^b	0.76 (0.64 to 0.86)	64 (17 to 109)^b	0.03 (−0.01 to 0.06)
+ NAG	0.93 (0.82 to 0.97)	79 (38 to 119)^b	0.13 (0.05 to 0.21)^b	0.74 (0.61 to 0.84)	24 (−30 to 78)	0.01 (−0.01 to 0.03)

^aAKI, Acute kidney injury; AUC-ROC, Area under the receiver operating characteristic curve; EPO, Erythropoietin; IDI, Integrated discrimination improvement index; IL, Interleukin; NAG, N-acetyl-β-d-glucosaminidase; NGAL, Neutrophil gelatinase-associated lipocalin; NRI, Net reclassification improvement index; TIMP-2, Tissue inhibitor of matrix metalloproteinase-2. ^bP < 0.05 vs. clinical model.

ISSN: 1364-8535